Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Bevacizumab±irinotecan is effective for treatment of recurrent malignant gliomas. However, the optimal duration of treatment has not been established. Materials and Methods Ninety-four consecutive patients with recurrent malignant glioma who were treated with bevacizumab at our institutions were identified. Patients who continued bevacizumab until tumor progression were enrolled in a late discontinuation (LD) group, while those who stopped bevacizumab before tumor progression were enrolled in an early discontinuation (ED) group. Landmark analyses were performed at weeks 9, 18, and 26 for comparison of patient survival between the two groups. Results Among 89 assessable patients, 62 (69.7%) and 27 (30.3%) patients were categorized as the LD and ED groups, respectively. According to landmark analysis, survival times from weeks 9, 18, and 26 were not significantly different between the two groups in the overall population. However, the LD group showed a trend toward increased survival compared to the ED group among responders. In the ED group, the median time from discontinuation to disease progression was 11.4 weeks, and none of the patients showed a definite rebound phenomenon. Similar median survival times after disease progression were observed between groups (14.4 weeks vs. 15.7 weeks, p=0.251). Of 83 patients, 38 (45.8%) received further therapy at progression, and those who received further therapy showed longer survival in both the LD and ED groups. Conclusion In recurrent malignant glioma, duration of bevacizumab was not associated with survival time in the overall population. However, ED of bevacizumab in responding patients might be associated with decreased survival.
Abstract
Purpose Bevacizumab±irinotecan is effective for treatment of recurrent malignant gliomas. However, the optimal duration of treatment has not been established. Materials and Methods Ninety-four consecutive patients with recurrent malignant glioma who were treated with bevacizumab at our institutions were identified. Patients who continued bevacizumab until tumor progression were enrolled in a late discontinuation (LD) group, while those who stopped bevacizumab before tumor progression were enrolled in an early discontinuation (ED) group. Landmark analyses were performed at weeks 9, 18, and 26 for comparison of patient survival between the two groups. Results Among 89 assessable patients, 62 (69.7%) and 27 (30.3%) patients were categorized as the LD and ED groups, respectively. According to landmark analysis, survival times from weeks 9, 18, and 26 were not significantly different between the two groups in the overall population. However, the LD group showed a trend toward increased survival compared to the ED group among responders. In the ED group, the median time from discontinuation to disease progression was 11.4 weeks, and none of the patients showed a definite rebound phenomenon. Similar median survival times after disease progression were observed between groups (14.4 weeks vs. 15.7 weeks, p=0.251). Of 83 patients, 38 (45.8%) received further therapy at progression, and those who received further therapy showed longer survival in both the LD and ED groups. Conclusion In recurrent malignant glioma, duration of bevacizumab was not associated with survival time in the overall population. However, ED of bevacizumab in responding patients might be associated with decreased survival.
참고문헌 (25)
- Norden AD, "Antiangiogenic therapies for high-grade glioma", Nat Rev Neurol, 5, pp.610~620 (2009)
- Vredenburgh JJ, "Bevacizumab plus irinotecan in recurrent glioblastoma multiforme", J Clin Oncol, 25, pp.4722~4729 (2007)
- Vredenburgh JJ, "Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma", Clin Cancer Res, 13, pp.1253~1259 (2007)
- Kreisl TN, "Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma", J Clin Oncol, 27, pp.740~745 (2009)
- Friedman HS, "Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma", J Clin Oncol, 27, pp.4733~4740 (2009)
- Mrugala MM, "Advances and challenges in the treatment of glioblastoma : a clinician's perspective", Discov Med, 15, pp.221~230 (2013)
- Wick W, "Bevacizumab and recurrent malignant gliomas: a European perspective", J Clin Oncol, 28, pp.e188~e189 (2010)
- Kesselheim JC, "Discontinuing bevacizumab in patients with glioblastoma : an ethical analysis", Oncologist, 16, pp.1435~1439 (2011)
- Zuniga RM, "Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma", J Neurooncol, 99, pp.237~242 (2010)
- Sherman WJ, "Outcome of discontinuing bevacizumab prior to malignant glioma progression", J Neurooncol, 111, pp.87~89 (2013)
- Ranpura V, "Treatment-related mortality with bevacizumab in cancer patients : a meta-analysis", JAMA, 305, pp.487~494 (2011)
- Brandsma D, "Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas", Lancet Oncol, 9, pp.453~461 (2008)
- Wen PY, "Updated response assessment criteria for high-grade gliomas : response assessment in neurooncology working group", J Clin Oncol, 28, pp.1963~1972 (2010)
- Anderson JR, "Analysis of survival by tumor response", J Clin Oncol, 1, pp.710~719 (1983)
- Griffioen AW, "Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients", Clin Cancer Res, 18, pp.3961~3971 (2012)
- Grothey A, "Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer : results from a large observational cohort study(BRiTE)", J Clin Oncol, 26, pp.5326~5334 (2008)
- Reardon DA, "Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients", Br J Cancer, 107, pp.1481~1487 (2012)
- Jain RK, "Normalizing tumor microenvironment to treat cancer : bench to bedside to biomarkers", J Clin Oncol, 31, pp.2205~2218 (2013)
- de Groot JF, "High-dose antiangiogenic therapy for glioblastoma:less may be more", Clin Cancer Res, 17, pp.6109~6111 (2011)
- Paez-Ribes M, "Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis", Cancer Cell, 15, pp.220~231 (2009)
- de Groot JF, "Tumor invasion after treatment of glioblastoma with bevacizumab : radiographic and pathologic correlation in humans and mice", Neuro Oncol, 12, pp.233~242 (2010)
- Norden AD, "Bevacizumab for recurrent malignant gliomas : efficacy, toxicity, and patterns of recurrence", Neurology, 70, pp.779~787 (2008)
- Iwamoto FM, "Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma", Neurology, 73, pp.1200~1206 (2009)
- Prados M, "Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab", Neuro Oncol, 13, pp.143~151 (2011)
- Miles D, "Disease course patterns after discontinuation of bevacizumab : pooled analysis of randomized phase III trials", J Clin Oncol, 29, pp.83~88 (2011)